Vitamin B3,Niacin / homoC Cancer Research Results

VitB3, Vitamin B3,Niacin: Click to Expand ⟱
Features:

Vitamin B3 (Niacin) = nicotinic acid (NA; pharmacologic drug + vitamin) and nicotinamide/niacinamide (NAM; vitamin; NAD+ precursor). Sources: human PK/PD and receptor biology; NAM high-dose AD Phase 2a; GPR109A mechanistic papers. Primary mechanisms (ranked):
1) NAD+/NADP+ precursor biology → redox/energy metabolism, mitochondrial support, PARP (DNA repair), sirtuins (stress-response signaling).
2) GPR109A (HCAR2) agonism (mainly nicotinic acid) → rapid anti-lipolysis; immune/epithelial anti-inflammatory signaling; can modulate colonic inflammation/carcinogenesis contextually.
3) High-concentration NAM enzyme inhibition → NAM can inhibit sirtuins (Class III “HDAC” activity) and other NAD+-consuming enzymes primarily at high (mM) exposures used in many in-vitro settings.
Bioavailability/PK relevance: NA absorbed rapidly (Tmax ~30–60 min) with short t½ (~1 h after 1 g); ER NA slows/lowers peak. NAM can reach much higher plasma levels only with gram-level dosing; typical supplement doses yield far lower systemic levels.
In-vitro vs oral exposure: many cancer-cell studies use 1–20 mM NAM/NA—commonly > physiologic/supplement systemic exposure; mM plasma is mainly plausible in therapeutic gram-dose NAM contexts (historically explored in radiosensitization), not routine supplementation.
Clinical evidence status: robust clinical use for dyslipidemia (NA; limited today by tolerability/toxicity); no established anticancer RCT benefit as monotherapy; NAM explored as adjunct/biomarker-modifier in select contexts; AD: Phase 2a high-dose NAM showed safety/tolerability but did not meet primary CSF p-tau biomarker endpoint.

Vitamin B3, also known as niacin, nicotinamide, or nicotinic acid, plays a crucial role in energy metabolism and DNA repair.
SEE ALSO NAD Target 
Forms of Vitamin B3 and Relevance
Form	                           Notes
Nicotinamide (NAM)	           Used in most AD and cancer research; does not cause flushing
Nicotinic acid	                   More common in cardiovascular use; causes flushing
Nicotinamide riboside (NR)	   NAD⁺ precursor with neuroprotective and anti-aging interest
Nicotinamide mononucleotide (NMN)  Also boosts NAD⁺; used in aging and cognitive studies

Cancers:
-Many cancers show depleted NAD⁺ levels. Restoring NAD⁺ via niacin or precursors may decrease growth
-Nicotinamide can inhibit sirtuins (SIRT1), which are overexpressed in some cancers
-anti-inflammatory
-In certain cancers, high NAD⁺ levels may support tumor metabolism (Warburg effect).

Alzheimer’s Disease (AD):
-reduces ROS
-Reduces neuroinflammation: Via SIRT1 activation and NF-κB inhibition.
-reduce tau phosphorylation and improve cognitive function.
-Boosting NAD⁺ levels may support memory formation

Food	                 Niacin (mg per 100g)	Notes
Tuna (yellowfin, cooked) ~22 mg	                Among the highest natural sources
Chicken breast (roasted) ~14.8 mg	        Lean, rich source
Turkey (light meat)	 ~12 mg	                Contains tryptophan, also converted to niacin
Beef liver (cooked)	 ~14 mg	                Extremely rich in many B vitamins
Salmon (cooked)	         ~8.5 mg                Also provides omega-3s
Pork (lean, cooked)	 ~6–8 mg	        Good source of both niacin and thiamine

Vitamin B3 (Niacin: Nicotinic Acid / Nicotinamide) — Cancer vs Normal Pathway Effects

Rank Pathway / Axis Cancer Cells (↑ / ↓ / ↔) Normal Cells (↑ / ↓ / ↔) TSF Primary Effect Notes / Interpretation
1 NAD+ pool / Redox capacity (NADH/NADPH) ↑ (often pro-survival; context-dependent) ↑ (cytoprotection; metabolic support) R→G Metabolic resilience Raising NAD+ can support tumor metabolism and stress tolerance; also supports normal-cell repair/mitochondria. Directional “benefit” is context- and tumor-genotype dependent.
2 PARP-mediated DNA repair (NAD+-consuming) ↑ capacity if NAD+↑; ↓ (high NAM only; model-dependent) ↑ repair capacity if NAD+↑; ↓ (high NAM only) R→G DNA damage response tuning Mechanistic bifurcation: NAD+ replenishment may enhance repair; high NAM (mM) can functionally inhibit NAD+-consuming enzymes in vitro/adjunct contexts.
3 Sirtuins (Class III “HDAC”) / stress-response programs ↔ (context-dependent); ↓ (high NAM only) ↔; ↓ (high NAM only) R→G Epigenetic + mitochondrial signaling modulation NAM is a known sirtuin reaction product and can inhibit sirtuin activity at sufficiently high concentrations; many “HDAC-like” effects in cell culture are high-dose NAM-driven.
4 GPR109A (HCAR2) signaling (nicotinic acid >> nicotinamide) ↑ anti-inflammatory / anti-tumor signaling (colon models; context-dependent) ↑ anti-inflammatory signaling; metabolic effects (adipose) P→R Immune–epithelial signaling shift GPR109A activation can suppress colonic inflammation and inflammation-associated carcinogenesis in preclinical models; translational relevance is tissue-context specific.
5 ROS ↔ (secondary; model-dependent) ↔ (secondary) R Redox buffering vs stress NADPH availability and mitochondrial function can shift ROS handling indirectly; not typically a “direct ROS drug” mechanism unless dosing/model forces oxidative stress.
6 Ca2+ signaling (notably flushing pathway; immune skin cells) ↔ (not core) ↑ (GPR109A-linked Ca2+ signaling in specific immune/skin contexts) P Trigger-proximal signaling Ca2+ signaling is mechanistically prominent for nicotinic-acid flushing biology; less central as a generalized anticancer axis.
7 Ferroptosis ↔ (indirect, context-dependent) ↔ R Lipid-peroxidation sensitivity (indirect) No canonical “niacin → ferroptosis” axis; any effect would likely be via NADPH/redox network shifts.
8 HIF-1α / Warburg metabolism ↔ (indirect) ↔ G Hypoxia/metabolic phenotype (indirect) NAD+ availability can influence glycolytic flux and mitochondrial balance, but direction is strongly model/tumor dependent.
9 Clinical Translation Constraint Dose-limited by tolerability/toxicity (NA flushing; hepatotoxicity risk with some regimens; metabolic side effects); many in-vitro concentrations exceed routine systemic exposure. — PK / Safety Anticancer claims are mostly preclinical/contextual; routine supplementation is unlikely to reproduce common in-vitro mM exposures.

TSF legend: P: 0–30 min (primary/rapid effects) | R: 30 min–3 hr (acute signaling + stress) | G: >3 hr (gene-regulatory adaptation; phenotype outcomes)


Vitamin B3 (Nicotinamide-focused) — Alzheimer’s Disease (AD) / Neurons-Glia (Normal-cell context)

Rank Pathway / Axis Cells (↑ / ↓ / ↔) TSF Primary Effect Notes / Interpretation
1 NAD+ pool / mitochondrial support ↑ R→G Bioenergetic resilience High-dose oral NAM can markedly raise plasma NAM (and related metabolites) in clinical settings; intended to support cellular redox/mitochondrial function.
2 Tau phosphorylation / proteostasis (hypothesized) ↓ (hypothesized; not confirmed clinically) G Biomarker-targeting rationale Phase 2a early-AD trial of high-dose NAM (48 weeks) was safe/tolerable but did not significantly reduce the primary CSF p-tau biomarker endpoint.
3 Sirtuins / Class III “HDAC” modulation (NAM as inhibitor at high exposure) ↓ (high concentration only) R→G Epigenetic/stress-response reprogramming Mechanistic rationale includes NAM effects on sirtuin-mediated signaling; clinical translation depends on achieving relevant CNS exposure.
4 Neuroinflammation ↔ (context-dependent) R→G Inflammatory tone shift (indirect) Potential secondary benefit via metabolic support and immune signaling; not established as a consistent clinical effect in AD.
5 ROS / Redox stress ↓ (secondary, indirect) R Oxidative stress buffering Likely mediated by improved NAD(P)H-linked buffering/mitochondrial function rather than direct antioxidant chemistry.
6 Clinical Translation Constraint — — Trial outcome limits High-dose NAM can raise plasma levels substantially; CNS penetration/target engagement may be variable; Phase 2a biomarker outcome negative.

TSF legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr
homoC, homocysteine: Click to Expand ⟱
Source:
Type:
Homocysteine is a sulfur-containing amino acid produced during the metabolism of methionine. Elevated homocysteine levels and alterations in its metabolic enzymes have been associated with various pathological processes, including oxidative stress, DNA damage, and inflammation.
-Elevated plasma homocysteine levels (hyperhomocysteinemia) are a well‐established risk factor for cardiovascular diseases.
-Some studies have suggested that high levels of homocysteine might be associated with an increased risk of certain cancers.
-Vitamins like folate, B6, and B12 are key regulators of homocysteine metabolism, some research has examined whether supplementation might modulate cancer risk. However, clinical outcomes have been mixed and further research is needed.

-Various clinical trials have shown that the oral supplementation of folic acid, B6, and B12 vitamins significantly lowers circulating homocysteine levels.
Scientific Papers found: Click to Expand⟱
4061- betaCar,  VitB12,  VitB6,  FA,  VitB3  Revisiting the Role of Vitamins and Minerals in Alzheimer’s Disease
- Review, AD, NA
*cognitive↑, *cognitive↑, *Inflam↓, *homoC↓, *TNF-α↓, *other↝, *memory↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Core Metabolism/Glycolysis ⓘ

homoC↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,   TNF-α↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 2,   memory↑, 1,  
Total Targets: 6

Scientific Paper Hit Count for: homoC, homocysteine
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:359  Target#:1257  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page